|
||
|
||
 |
The company's Rapid Test technology platform presents opportunities for diversification into a broader range of testing for infectious diseases, nutrition, drug monitoring and cancer markers. Possibilities are |  |
 |
|
Continued innovation of rapid test devices using serum, saliva and whole blood. | ||
|
Strategic partnerships with major diagnostic and pharmaceutical companies to facilitate global introduction and distribution of products. | ||
|
Maximal use of patent process to protect all products and technology developed by SDS | ||
Disclaimer |
|||